TITLE

rhBMP-2/ACS Grafts Versus Autogenous Cancellous Marrow Grafts in Large Vertical Defects of the Maxilla: An Unsponsored Randomized Open-Label Clinical Trial

AUTHOR(S)
Marx, Robert E.; Armentano, Lawrence; Olavarria, Alberto; Samaniego, Juan
PUB. DATE
April 2011
SOURCE
Oral & Craniofacial Tissue Engineering;2011, Vol. 1 Issue 1, p33
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: This study compared the histologic parameters and outcomes of two types of grafts in large vertical maxillary defects: a composite graft of recombinant human bone morphogenetic protein-2/ acellular collagen sponge (rhBMP-2/ACS), crushed cancellous freeze-dried allogeneic bone (CCFDAB), and platelet-rich plasma (PRP); and size-matched 100% autogenous grafts. Materials and Methods: Twenty patients each were treated with a composite graft, which contained 1.05 mg rhBMP-2/ACS per two-tooth segment together with CCFDAB and PRP, or a 100% autogenous graft prior to implant placement. Grafting material was contained within a titanium mesh crib. Results: Two grafts in each group were lost as a result of early mesh exposure and infection. Three grafts in each group developed a late exposure of the mesh that did not affect bone regeneration. The remaining 18 autogenous grafts all regenerated sufficient bone for implant restoration (100%), and 17 of 18 (97.4%) of the composite grafts regenerated sufficient bone for implant restoration. The autogenous grafts included 54%±10% of new viable bone but also included residual nonviable graft particles. The composite grafts contained 59%±12% viable new bone and no remaining nonviable bone particles. The composite grafting technique resulted in less blood loss and shorter surgical time but greater and longer-lasting edema. The costs of both grafts were nearly equal. Conclusion: A composite graft of rhBMP-2/ACS-CCFDAB-PRP regenerates bone in large vertical ridge augmentations as predictably as 100% autogenous graft with less morbidity, equal cost, and more viable new bone formation without residual nonviable bone particles, but with more edema. This composite graft represents an in situ tissue engineering concept that is able to achieve results equivalent to autogenous grafts in large vertical ridge augmentations without donor bone harvesting.
ACCESSION #
61029749

 

Related Articles

  • Recombinant human bone morphogenetic protein type 2 in the reconstruction of atrophic maxilla: Case report with long-term follow-up. Zétola, André Luiz; Verbicaro, Thalyta; Littieri, Sahara; Larson, Rafaela; Giovanini, Allan Fernando; Deliberador, Tatiana Miranda // Journal of Indian Society of Periodontology;Nov/Dec2014, Vol. 18 Issue 6, p781 

    Autologous bone is reported by scientific literature as the gold standard for the replacement of the bone loss in maxillary atrophic area. Notwithstanding, this grafting type shows several disadvantages as: The procedure morbidity, limited size of the graft and longer recovering time....

  • Bone Reconstruction following Application of Bone Matrix Gelatin to Alveolar Defects: A Randomized Clinical Trial. Bayat, M.; Heravi, F. Momen; Mahmoudi, M.; Bahrami, N. // International Journal of Organ Transplantation Medicine;2015, Vol. 6 Issue 4, p176 

    Background: Conventional dentoalveolar osseous reconstruction often involves the use of graft materials with or without barrier membranes. Objective: To evaluate the efficacy of bone induction by bone matrix gelatin (BMG), delivered on an absorbable collagen sponge (ACS), compared to a placebo...

  • A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). McKay, William; Peckham, Steven; Badura, Jeffrey // International Orthopaedics;Dec2007, Vol. 31 Issue 6, p729 

    The combination of recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge (ACS) carrier has been shown to induce bone formation in a number of preclinical and clinical investigations. In 2002, rhBMP-2/ACS at a 1.5-mg/cc concentration (INFUSE® Bone Graft,...

  • Influence of bone morphogenetic protein on articular cartilage regeneration following periosteal grafting. Yimin Zhang; Xin Jiang; Yongzhi Guo // Journal of Biomedical Science & Engineering;Jan2013, Vol. 6 Issue 1, p25 

    Background: Autologous periosteal grafting is used as treatment for articular cartilage defect. Objective: To study the effect of bone morphogenetic protein (BMP) on articular cartilage regeneration following periosteal grafting. Methods: 16 healthy 15-week-old New Zealand white rabbits of both...

  • Osteoinductive growth factors can aid bone growth in orthopedic procedures. Rapp, Susan M. // Orthopedics Today;Jul2008, Vol. 28 Issue 7, p46 

    The article focuses on issues related to bone morphogenetic proteins (BMP) discussed by Doctor Scott D. Boden at the American Academy of Orthopaedic Surgeons (AAOS) and Orthopaedic Research Society annual meetings held in San Francisco, California from March 5-9, 2008. Boden mentioned the...

  • Dibotermin-α.  // Reactions Weekly;3/20/2010, Issue 1293, p21 

    The article describes two cases of women who developed swelling after receiving dibotermin-α through an anterior lumbar interbody fusions with large infuse bone graft kits.

  • An Osteoconductive, Osteoinductive, and Osteogenic Tissue-Engineered Product for Trauma and Orthopaedic Surgery: How Far Are We? Khan, Wasim S.; Rayan, Faizal; Dhinsa, Baljinder S.; Marsh, David // Stem Cells International;2012, p1 

    The management of large bone defects due to trauma, degenerative disease, congenital deformities, and tumor resection remains a complex issue for the orthopaedic reconstructive surgeons. The requirement is for an ideal bone replacement which is osteoconductive, osteoinductive, and osteogenic....

  • Recombinant Human Bone Morphogenetic Protein-2: Use in Spinal Fusion Applications. Sandhu, Harvinder S.; Khan, Safdar N. // Journal of Bone & Joint Surgery, American Volume;Aug2003 Supplement, Vol. 85-A, p89 

    Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been tested for use in spinal fusion in several completed prospective, randomized clinical trials, beginning in 1997. After rhBMP-2 was demonstrated to be equivalent to autogenous iliac bone graft with regard to both fusion rate and...

  • Bone growth material looks promising. Moore, Amy Slugg // RN;Nov99, Vol. 62 Issue 11, p96 

    Relates the potential of bone morphogenic protein for the replacement of missing bone in humans.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics